Salsalate has no effect on insulin secretion but decreases insulin clearance: A randomized, placebo-controlled trial in subjects without diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 6, 2015, Pages 608-612

  Penesova, A ^a,b   Koska, J ^a,c   Ortega, E ^a,d   Bunt, J C ^a   Bogardus, C ^a   de Courten, B ^a,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c Phoenix VA Healthcare System   (United States)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e MONASH UNIVERSITY   (Australia)

Author keywords

C peptide; Insulin secretion; Salicylates; Salsalate; Stepped hyperglycaemia

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; PLACEBO; SALSALATE; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOCRINE FUNCTION TEST; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LETTER; OBESITY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; STEPPED GLUCOSE INFUSION; ADULT; BLOOD; DRUG EFFECTS; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; SECRETION (PROCESS); SECRETION RATE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; C-PEPTIDE; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; OBESITY; SALICYLATES; SECRETORY RATE;

EID: 84928428363     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12450     Document Type: Letter

References (12)

1. Fernandez-Real JM, Lopez-Bermejo A, Ropero AB et al. Salicylates increase insulin secretion in healthy obese subjects. J Clin Endocrinol Metab 2008; 93: 2523-2530.
2. Koska J, Ortega E, Bunt JC et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52: 385-393.
3. Goldfine AB, Conlin PR, Halperin F et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013; 56: 714-723.
4. Kim SH, Liu A, Ariel D et al. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. Diabetes Care 2014; 37: 1944-1950.
5. Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab 1983; 57: 1102-1106.
6. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 1985; 28: 671-676.
7. Giugliano D, Torella R, Siniscalchi N, Improta L, D'Onofrio F. The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man. Diabetologia 1978; 14: 359-362.
8. Micossi P, Pontiroli AE, Baron SH et al. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes 1978; 27: 1196-1204.
9. Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes 1978; 27: 750-756.
10. Gautier JF, Wilson C, Weyer C et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes 2001; 50: 1828-1833.
11. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
12. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G. Insulin clearance in obesity. J Am Coll Nutr 2003; 22: 487-493.